Company
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
FDA approval of a generic extended-release topiramate formulation; regulatory action that expands market access but does not itself report clinical efficacy or comparative trial data.
APR 28, 2026 · REGULATORY APPROVAL
U.S. Food and Drug Administration
FDA approval of a generic eltrombopag olamine formulation; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative benefit data.